Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experience
Ihunayachi Ohuabunwa(Washington University in St. Louis), Olalekan O. Oluwole(Vanderbilt University), Eden Biltibo(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University Medical Center), Ali Nur(Vanderbilt University Medical Center), Shakthi Bhaskar(Vanderbilt University Medical Center), James H. Jerkins(Vanderbilt University Medical Center), Muhamed Baljević(Vanderbilt University Medical Center), B. N. Savani(Vanderbilt University Medical Center), Phavina A Akhom(Vanderbilt University Medical Center), B Dholaria(Vanderbilt University Medical Center), Brittney Baer(Vanderbilt University Medical Center), Salyka Sengsayadeth(VA Tennessee Valley Healthcare System), Leslie Mader(Vanderbilt University Medical Center), Vivek Patel(Vanderbilt University Medical Center), Grace Johnson Mercadante(Vanderbilt University Medical Center), Nancy Long(Vanderbilt University Medical Center), Sarah Moseley(Vanderbilt University Medical Center), Megan Wanca(Vanderbilt University Medical Center), Adetola Kassim(Vanderbilt University Medical Center), David Morgan(Vanderbilt University Medical Center), Andrew Jallouk(Vanderbilt University Medical Center)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782